다발성 골수종 치료제 시장 : 약제 클래스별, 치료 단계, 치료 레지멘, 투여 경로, 환자 연령, 치료 단계, 환자 유형, 최종사용자별 - 시장 예측(2026-2032년)

The Multiple Myeloma Drug Market is projected to grow by USD 13.46 billion at a CAGR of 7.29% by 2032.

Multiple Myeloma Drug Market Introduction

Multiple myeloma is a plasma cell malignancy and remains one of the most treatment-intensive segments of hematologic oncology. The disease is characterized by recurrent relapse, clonal evolution, bone marrow involvement, immunosuppression, renal complications, anemia, and bone disease, creating sustained demand for effective multiple myeloma drugs across newly diagnosed, relapsed, and refractory settings.

The market is being reshaped by proteasome inhibitors, immunomodulatory agents, corticosteroid combinations, anti-CD38 monoclonal antibodies, selective nuclear export inhibitors, BCMA-targeted therapies, CAR-T cell therapies, bispecific antibodies, and emerging cereblon E3 ligase modulators. Clinical practice continues to move toward earlier use of combination regimens, measurable residual disease assessment, and personalized sequencing based on patient fitness, cytogenetic risk, prior exposure, and treatment response.

According to widely used oncology references and public health sources such as WHO/IARC GLOBOCAN, the American Cancer Society, NCCN, ESMO, FDA, and EMA, multiple myeloma incidence rises sharply with age and remains a major cause of hematologic cancer mortality despite substantial therapeutic advances. This creates a durable need for innovation that improves depth of response, prolongs progression-free survival, reduces treatment burden, and expands access to advanced therapies.

Transformative Shifts in the Multiple Myeloma Drug Landscape

The multiple myeloma drug landscape is undergoing a structural shift from traditional chemotherapy-centered care to multi-mechanism, immune-based, and biomarker-informed treatment strategies. Anti-CD38 antibodies have become foundational in many frontline and relapse regimens, while BCMA-directed CAR-T therapies and bispecific antibodies are redefining expectations in heavily pretreated relapsed or refractory multiple myeloma.

A second transformative shift is the movement of high-efficacy therapies into earlier lines of treatment. Regulatory decisions and clinical trial results increasingly support the use of quadruplet regimens, maintenance optimization, and risk-adapted approaches that aim to deepen response and extend remission. At the same time, clinicians must manage cumulative toxicities such as cytopenias, infections, neuropathy, thromboembolic risk, and cytokine release syndrome.

Commercial strategy is also changing. Manufacturers are investing in subcutaneous formulations, outpatient administration models, companion diagnostics, real-world evidence generation, and payer-facing value dossiers. As more mechanisms enter the market, competitive differentiation depends on survival outcomes, safety, convenience, manufacturability, access programs, and evidence in high-risk populations.

Cumulative Impact of Artificial Intelligence on Multiple Myeloma Drugs

Artificial intelligence is becoming an enabling layer across multiple myeloma drug discovery, development, diagnosis, and treatment optimization. In research, AI-supported target discovery, protein modeling, screening prioritization, and translational analytics are helping identify novel antigens, resistance pathways, and rational combination strategies. These tools are particularly relevant in a disease marked by genomic heterogeneity and treatment-induced clonal evolution.

In clinical development, AI can improve trial design by supporting patient stratification, site selection, eligibility matching, synthetic control exploration, and real-time safety monitoring. For multiple myeloma, where endpoints such as progression-free survival, overall survival, minimal residual disease negativity, and quality of life are central, advanced analytics can strengthen evidence generation when used with validated datasets and transparent governance.

In care delivery, AI-enabled decision support may help interpret laboratory trends, imaging, cytogenetics, sequencing history, and adverse event risk. However, adoption depends on clinical validation, interoperability, bias mitigation, data privacy, and regulatory oversight. The strongest near-term impact is expected where AI augments clinician decision-making rather than replacing specialist judgment.

Key Regional Insights Across the Multiple Myeloma Drug Market

North America remains a leading region for multiple myeloma drug innovation due to high oncology spending, rapid uptake of FDA-approved therapies, extensive clinical trial infrastructure, and strong specialist networks. The United States anchors regional demand through broad adoption of anti-CD38 antibodies, CAR-T therapy, bispecific antibodies, and evidence-based guidelines, while Canada emphasizes health technology assessment and publicly funded access pathways. Across the region, treatment standards are strongly influenced by regulatory review, guideline updates, transplant eligibility assessment, specialty pharmacy distribution, and real-world safety monitoring.

Europe is defined by EMA approvals, national reimbursement negotiations, and guideline-driven adoption across major markets. The European Union supports harmonized regulatory oversight, but access timelines vary by country, particularly for high-cost cell and gene therapies. The United Kingdom, Germany, France, Italy, and Spain remain important markets due to specialized hematology centers, formal health technology assessment systems, and real-world evidence programs that evaluate clinical benefit, added therapeutic value, and budget impact.

Asia-Pacific is expanding as China, Japan, South Korea, Australia, and India increase access to novel myeloma drugs, local clinical trials, and domestic biopharmaceutical development. China's regulatory modernization and growing oncology infrastructure are improving availability of innovative therapies, while Japan's aging population and advanced hematology practice support strong clinical demand. Latin America shows growing adoption in Brazil and Mexico but continues to face reimbursement, diagnostic capacity, and specialist access constraints. The Middle East, led by GCC health systems, is investing in oncology centers, medical tourism, and advanced therapeutics, while Africa remains underpenetrated due to limited specialist access, late diagnosis, constrained reimbursement, and uneven availability of advanced diagnostics.

Key Group Insights for Multiple Myeloma Drug Commercial Strategy

The G7 remains central to the multiple myeloma drug market because it includes major innovation, reimbursement, and clinical guideline economies such as the United States, Canada, Japan, Germany, France, Italy, and the United Kingdom. These countries shape global standards through regulatory decisions, pivotal trials, health technology assessments, transplant center networks, and adoption of advanced therapies including CAR-T cells and bispecific antibodies.

The European Union provides a structured regulatory and pharmacovigilance environment through EMA oversight, while individual member states determine pricing and reimbursement. This creates a market where clinical value must be matched with cost-effectiveness evidence, real-world outcomes, budget impact management, and equitable access strategies. NATO countries collectively include advanced healthcare systems with strong demand for secure pharmaceutical supply chains, resilient medicine access, and coordinated preparedness for critical therapies, including oncology biologics and cell therapies.

BRICS economies are increasingly important due to large patient populations, expanding cancer infrastructure, and growing domestic pharmaceutical capabilities in China, India, Brazil, Russia, and South Africa. China and India are particularly relevant for clinical development, manufacturing capacity, biosimilars, and broader access initiatives, while Brazil and South Africa highlight the need for public-sector affordability strategies. ASEAN markets are improving oncology access through public-private investment, regional procurement strategies, and expanding specialist care, although availability of premium biologics remains uneven across member countries. GCC countries are prioritizing specialty care modernization, advanced hospital infrastructure, international clinical collaborations, and access to innovative oncology drugs for high-complexity hematologic malignancies.

Key Country Insights in the Multiple Myeloma Drug Market

The United States is the most influential country market for multiple myeloma drugs because of rapid FDA approvals, high clinical trial activity, strong specialty pharmacy networks, advanced transplant and cellular therapy capacity, and early adoption of novel mechanisms. Canada follows a more centralized access model, with reimbursement decisions shaped by clinical benefit, cost-effectiveness, pan-Canadian review processes, and provincial implementation. Mexico and Brazil are important Latin American markets where demand is rising, but access depends on public coverage, private insurance, oncology center concentration, and availability of specialized hematology services.

In Europe, the United Kingdom, Germany, France, Italy, and Spain represent major demand centers with established hematology networks and formal health technology assessment processes. Germany often provides comparatively early post-approval access within Europe, while France, Italy, and Spain emphasize negotiated reimbursement, evidence of added therapeutic value, and managed access considerations. The United Kingdom combines guideline-driven care with cost-effectiveness assessment and specialized cancer networks. Russia maintains domestic oncology demand but faces access variability linked to procurement dynamics, local availability, and geopolitical constraints.

In Asia-Pacific, China is expanding through domestic innovation, regulatory reform, broader oncology insurance coverage, and rising clinical trial participation. Japan remains a high-value market with advanced clinical practice, strong safety monitoring, and an aging population that increases the clinical relevance of tolerable long-term regimens. India has a substantial patient base and strong generics and biosimilars capabilities, though affordability remains a barrier for premium therapies and advanced cell-based treatment. Australia and South Korea show high standards of oncology care, reimbursement scrutiny, active clinical research ecosystems, and strong interest in innovative immune-based treatments for relapsed or refractory multiple myeloma.

Actionable Recommendations for Multiple Myeloma Drug Leaders

Industry leaders should prioritize differentiated clinical evidence that demonstrates meaningful improvements in progression-free survival, overall survival, minimal residual disease negativity, safety, convenience, and patient-reported outcomes. As the treatment landscape becomes crowded, products must show value in defined patient groups such as high-risk cytogenetics, frail older adults, renal impairment, prior anti-CD38 exposure, triple-class refractory disease, and patients requiring outpatient-friendly treatment options.

Organizations should invest in access strategies early, including health economic models, real-world evidence, outcomes-based contracting, and patient support programs. For advanced therapies, manufacturing reliability, vein-to-vein time, outpatient administration readiness, referral pathway development, infection prevention, and toxicity management protocols are critical competitive factors.

Partnerships with academic centers, diagnostic developers, AI platforms, contract manufacturers, and regional distributors can accelerate trial execution and market penetration. Leaders should also strengthen pharmacovigilance, equitable access planning, supply chain resilience, and lifecycle management through new formulations, rational combinations, label expansion, and earlier-line indications.

Research Methodology for the Multiple Myeloma Drug Analysis

This executive summary is built using secondary research principles aligned with pharmaceutical market intelligence best practices. Sources considered include public regulatory databases, clinical guideline organizations, peer-reviewed oncology literature, cancer epidemiology resources, clinical trial registries, health technology assessment frameworks, and publicly available policy documents.

The analysis emphasizes verified and widely recognized evidence from organizations such as the FDA, EMA, WHO/IARC, NCCN, ESMO, national cancer agencies, and published clinical trial data. Market interpretation focuses on therapy class evolution, regional access dynamics, patient segmentation, regulatory activity, clinical development trends, and adoption drivers rather than unsupported numerical forecasting.

Insights were synthesized through triangulation of epidemiology, treatment guidelines, regulatory approvals, clinical development trends, reimbursement considerations, safety requirements, and care delivery constraints. The methodology favors data-backed interpretation, transparent assumptions, and practical relevance for pharmaceutical manufacturers, investors, payers, providers, and commercial strategy teams.

Conclusion: Future Outlook for Multiple Myeloma Drugs

The multiple myeloma drug market is advancing rapidly as immunotherapy, targeted therapy, and precision treatment strategies reshape standards of care. While the disease remains largely incurable for many patients, deeper responses and longer remission periods are increasingly achievable through combination regimens, maintenance strategies, measurable residual disease assessment, and novel immune-directed therapies.

Future success will depend on clinical differentiation, earlier-line expansion, access to advanced therapies, real-world outcomes, manufacturing readiness, and the ability to serve diverse patient populations across mature and emerging markets. Organizations that combine scientific innovation with evidence-based access planning, AI-enabled development, supply chain resilience, and patient-centered delivery models will be best positioned to lead the next phase of multiple myeloma treatment.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Multiple Myeloma Drug Market, by Drug Class

• 7.1. Histone Deacetylase Inhibitors
• 7.2. Immunomodulatory Agents
  • 7.2.1. Lenalidomide
  • 7.2.2. Pomalidomide
  • 7.2.3. Thalidomide
• 7.3. Monoclonal Antibodies
  • 7.3.1. Daratumumab
  • 7.3.2. Elotuzumab
  • 7.3.3. Isatuximab
• 7.4. Proteasome Inhibitors
  • 7.4.1. Bortezomib
  • 7.4.2. Carfilzomib
  • 7.4.3. Ixazomib

8. Multiple Myeloma Drug Market, by Line Of Therapy

• 8.1. First Line
• 8.2. Second Line
• 8.3. Third And Beyond

9. Multiple Myeloma Drug Market, by Treatment Regimen

• 9.1. Combination Therapy
  • 9.1.1. Doublet Regimen
  • 9.1.2. Quadruplet Regimen
  • 9.1.3. Triplet Regimen
• 9.2. Monotherapy

10. Multiple Myeloma Drug Market, by Route Of Administration

• 10.1. Intravenous
• 10.2. Oral
• 10.3. Subcutaneous

11. Multiple Myeloma Drug Market, by Patient Age

• 11.1. Sixty And Above
• 11.2. Under Sixty

12. Multiple Myeloma Drug Market, by Line of Treatment

• 12.1. First-Line Therapy
• 12.2. Second-Line Therapy
• 12.3. Third-Line and Beyond

13. Multiple Myeloma Drug Market, by Patient Type

• 13.1. Newly Diagnosed Patients
• 13.2. Relapsed Patients
• 13.3. Refractory Patients

14. Multiple Myeloma Drug Market, by End-User

• 14.1. Hospitals
• 14.2. Specialty Clinics
• 14.3. Cancer Research Centers

15. Multiple Myeloma Drug Market, by Region

• 15.1. Asia-Pacific
• 15.2. North America
• 15.3. Latin America
• 15.4. Europe
• 15.5. Middle East
• 15.6. Africa

16. Multiple Myeloma Drug Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Multiple Myeloma Drug Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025

19. Company Profiles

• 19.1. AbbVie Inc.
• 19.2. Adaptive Biotechnologies Corporation
• 19.3. Amgen Inc.
• 19.4. BeiGene, Ltd.
• 19.5. Bristol-Myers Squibb Company
• 19.6. Celgene Corporation
• 19.7. Cellectis S.A.
• 19.8. Daiichi Sankyo Company, Limited
• 19.9. Gilead Sciences, Inc.
• 19.10. GlaxoSmithKline plc
• 19.11. Ichnos Glenmark Innovation
• 19.12. Johnson & Johnson Services, Inc.
• 19.13. Karyopharm Therapeutics Inc.
• 19.14. Legend Biotech Corporation
• 19.15. Merck & Co., Inc.
• 19.16. MorphoSys AG
• 19.17. Novartis AG
• 19.18. Oncopeptides AB
• 19.19. Pfizer Inc.
• 19.20. PharmaMar, S.A.
• 19.21. Regeneron Pharmaceuticals, Inc.
• 19.22. Sanofi
• 19.23. Takeda Pharmaceutical Company Limited
• 19.24. Teva Pharmaceutical Industries Ltd.